| http://www.w3.org/ns/prov#value | - t received prior anti-TNF-alpha therapy for at least 48 w...Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting... following treatment with bortezomib and an immunomodulatory agent, such as thalidomide or lenalidomide, and were refractory to their last treatment. eighty percent of patients received at least four prior treatments.
|
